Lexicon Pharmaceuticals (LXRX) Cash & Equivalents (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash & Equivalents data on file, last reported at $38.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 39.43% year-over-year to $38.1 million in Q1 2026; TTM through Mar 2026 was $38.1 million, a 39.43% decrease from a year earlier, with the FY2025 full-year figure at $34.3 million, down 48.5% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $38.1 million, up from $34.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LXRX reached as high as $102.3 million in Q2 2023 and fell as low as $18.8 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $44.6 million across 5 years, with a median of $35.6 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 79.55% in 2022 and soared 376.79% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $46.3 million in 2022, then sank by 51.53% to $22.5 million in 2023, then jumped by 196.71% to $66.7 million in 2024, then tumbled by 48.5% to $34.3 million in 2025, then rose by 10.96% to $38.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $38.1 million in Q1 2026, $34.3 million in Q4 2025, and $49.7 million in Q3 2025.